Structure Therapeutics (GPCR) reported highly positive Phase 2 ACCESS II data for aleniglipron, achieving ~16% placebo-adjusted weight loss with strong statistical significance and no plateau.
The tech industry’s expansion of data centers is emerging as a wedge issue in the midterms, as candidates weigh economic opportunity against the associated strain on voters’ utility bills. In the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results